Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T18:01:03.719Z.
Calculation as of: 2026-10-06T18:01:03.719Z.
Quote observation: 2026-10-06T18:00:18.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a5ea7848df566bb1fba137e14a23bd7a424b67da13a14cf2752e181034030ce3
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$33.26M
EV/Sales Ratio
0.20x
TTM Avg
15.56x
3Y Avg
19.81x
5Y Avg
321.73x
Market Cap
$34.21M
EV/Sales Ratio
0.44x
TTM Avg
0.48x
3Y Avg
0.66x
5Y Avg
0.78x
Market Cap
$32.82M
EV/Sales Ratio
4.04x
TTM Avg
4.11x
3Y Avg
4.50x
5Y Avg
18.25x
Market Cap
$32.68M
EV/Sales Ratio
0.52x
TTM Avg
0.48x
3Y Avg
0.60x
5Y Avg
0.58x
Market Cap
$35.06M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$35.69M
EV/Sales Ratio
3.21x
TTM Avg
7.33x
3Y Avg
18.71x
5Y Avg
16.11x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| HeartBeam, Inc. (BEAT) | $33.59M | N/A | N/A | N/A | N/A |
| Aligos Therapeutics, Inc. (ALGS)vs › | $33.26M | 0.20x | 15.56x | 19.81x | 321.73x |
| Accuray Incorporated (ARAY)vs › | $34.21M | 0.44x | 0.48x | 0.66x | 0.78x |
| Scilex Holding Company (SCLX)vs › | $32.82M | 4.04x | 4.11x | 4.50x | 18.25x |
| Grace Therapeutics, Inc. (GRCE)vs › | $34.42M | N/A | N/A | N/A | N/A |
| Elutia Inc (ELUT)vs › | $34.48M | 2.09x | 1.98x | 3.00x | 2.66x |
| Rockwell Medical, Inc. (RMTI)vs › | $32.68M | 0.52x | 0.48x | 0.60x | 0.58x |
| BriaCell Therapeutics Corp. (BCTX)vs › | $35.06M | N/A | N/A | N/A | N/A |
| EUDA Health Holdings Limited (EUDA)vs › | $35.69M | 3.21x | 7.33x | 18.71x | 16.11x |
| Nortech Systems Incorporated (NSYS)vs › | $31.44M | 0.38x | 0.41x | 0.37x | 0.39x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
